Starpharma: "Parkettgeflüster".. Sammelthread - wann kommen die 1. Kaufempfehlungen? (Seite 173)

[CyberCoach]

Wieso nur einem großen Pharmakonzern?
Und wieso nur HIV?
Und wieso nur medizinische Anwendung?
Und wie sieht es mit den Armeeaufträgen aus?
Und war da nicht was mit einem "Home-Defense-Ministry" bei unseren Amifreunden, die ja schon richtig feste die 49% Tochter von Starpharma in das Nanoprogramm einbezogen hat?
Wir reden doch bei dieser Technologie nicht nur über HIV und Geschlechtskrankeiten, sondern auch über vernachlässigbare Märkte wie
Influenza (Grippe)
Cholera
Ebola
usw.

Eine kleine Liste hatte ich ja schon reingestellt.

Übrigens, diese Technik über Dendrimere weisses Licht einzufangen und rotes Laserlicht abzugeben .............

Mein Tip: Strong Invest !

Gruss,
cybercoach

[flappmann28]

@ Lost Horizon

Ist zwar ein gesperrter Bereich, sieht mir aber ganz nach Starpharma aus. Wenn dieses Gel wirklich auch bei Menschen funktioniert, das wäre der Hammer. Was meint ihr, was diese Lizens einem großen Pharmakonzern Wert wäre?

[Bogi2003]

@WOchmann,
nein. Bin erst morgen wieder liquide..

[LostHorizons]

Auf dieser Seite wird von heutigen News gesprochen
hat das was vielleicht mit Starpharma zu tun.
Ist geschützter Bereich. Wenn nicht dann bitte ich um Entschuldigung.


http://www.biotechnews.com.au/

HIV: new drugs show early promise 12/02/2004 15:14:25
New classes of HIV drugs that prevent the virus from infecting cells are showing promise in early trials, researchers have reported. More...


Grüße Lost H.

[WOchmann]

Na geht doch, RT in Frankfurt 0,56€ Bid 0,55€ Ask 0,57€
Bogi, wars Du das mit den 0,56€ ?
GRuß
WOchmann

[Bogi2003]

...das ich selbst entscheiden muss (und werde ) ist klar.
Mich haben einfach nur mal eure Meinungen interessiert.
Danke.

[CyberCoach]

Zwei Kurspunkte triffst du nie:
Den idealen Einstieg
und
den idealen Ausstieg.

Heute kostet die Aktie 55 cent bei kleinen Umsätzen. Ich bin seit 71 cent dabei und kaufe ab und zu. Manche hier gehen von 45 cent möglichem Einstieg aus, manche von 51 cent, ich selber steige in Scheiben ein, jeden Tag etwas, damit ich auf einen vernünftigen Mischkurs komme.

Wer soll dir die Entscheidung abnehmen?????

[WOchmann]

Was immer Du auch tust, die Entscheidung mußt Du selbst fällen. Ich bin soeben bei 0,55€ in Frankfurt rein.
Ich denke die Konsolidierung war ganz normal, das Alltimehigh bei 1 AUD wurde erreicht und der Wert ist abgeprallt. Es sollte in den nächsten Tagen wieder die Marke von 1A$ in Angriff genommen werden.
Viel Erfolg und Gruß
WOchmann

[Bogi2003]

ein sehr interessanter Wert.
Allerdings ging es ja wieder ein wenig abwärts.
Sollte ich mit dem Einstiegszeitpunkt noch ein paar Tage warten?
Was denkt Ihr?

[CyberCoach]

Je mehr ich micht mit diesen Dendrimeren befasse, desto mehr Appetit kriege ich auf Starpharma. Logisch, das die Frau Hörrlein das Markt- und Umsatzvolumen nicht abschätzen kann. Wie bewertet man denn zum Beispiel einen umfassenden Schutz gegen alle Geschlechtskrankheiten zum Beispiel?????

Hier ein Ausschnitt von www.starpharma.com

Sexually Transmitted Diseases
A global epidemic...

In the US, sexually transmitted diseases (STDs) affect more than 13 million people annually. It is estimated that more than 4 million Americans are infected by Chlamydia each year and that chlamydial infections and the other problems they cause cost Americans more than US$2 billion a year. It is estimated that genital herpes affects about 60 million Americans. In 1999, it was estimated that the annual cost of all STDs was more than US$10 billion annually. Research has also shown that having an STD makes infection with HIV more likely. Throughout the world, more than 42 million people are living with HIV, and approximately 50 percent of the adults living with HIV are women. 8000 children and young people aged 24 years and under were infected with HIV every day in 2002. An additional 45 million people are estimated to be infected with HIV between 2003 and 2010.

In March 1999, after consultation with world experts in the field of STDs, Starpharma initiated a research program to develop a dendrimer-based topical microbicide. This research has resulted in the development of VivaGel™, which is a topical microbicide that can potentially prevent or reduce the transmission of HIV and other STDs when applied to the vagina or rectum prior to sexual intercourse. Other products being investigated for development in this area include a topical treatment for recurrent genital herpes infection.
Starpharma’s contribution to a global effort...

VivaGel™ is a water-based gel that contains the polyvalent, polylysine dendrimer, SPL7013, as the active ingredient. SPL7013 has shown activity against multiple viral STDs:

* Human immunodeficiency virus (HIV)
* Chlamydia
* Herpes simplex virus
* Hepatitis B virus
* Human papilloma virus (genital warts)

A safe and effective microbicide will offer women, who are generally more vulnerable to HIV infection than men due to biological, sociological and cultural factors, an alternative to dependence on male condoms for STD prevention. Initiatives to encourage the development of microbicides and to ensure that a safe and effective microbicide is accessible to all women include government funded R&D support and pricing subsidies.

In July 2003, Starpharma gained clearance to proceed with a Phase I clinical trial under US Food & Drug Administration (FDA) regulations to test the safety of VivaGel™ in humans. These clinical trials commenced in Adelaide, Australia, in January 2004.

For a summary of the licensing opportunities arising out of this project visit LICENSING OPPORTUNITIES.

For more information, see flyer Product Focus: VivaGel™.
Respiratory Viruses

Starpharma’s dendrimers have shown exciting activity individually against several respiratory diseases including respiratory syncitial virus (RSV), influenza and adenovirus. Starpharma has an active dendrimer-based drug discovery program aimed at developing inhalational, respiratory pharmaceuticals. Dendrimers are currently being assessed against a range of respiratory viruses and emerging pathogens (e.g. SARS).

For a summary of the licensing opportunities arising out of this project visit LICENSING OPPORTUNITIES.
Systemic Viral Diseases

Systemic viral diseases include hepatitis B virus (HBV). Chronic HBV infection is a global health problem with approximately 350 million carriers worldwide. Many of these carriers develop severe liver disease, such as cirrhosis and cancer. While there is a vaccine for HBV available, it is not widely distributed. There are also few therapeutic options available. Starpharma is developing dendrimers as novel HBV therapeutic agents. Some dendrimers have demonstrated broad-spectrum antiviral activity and early studies suggest a novel mechanism of action compared with existing HBV therapeutics.
Oncology

Starpharma oncology projects focus on:

* small molecules to inhibit angiogenesis;
* the development of a dendrimer-cisplatin complex for drug delivery.

Angiogenesis...

Angiogenesis is the process of small blood vessel formation and growth. Angiogenesis has been associated with the growth and spread of cancer. Starpharma has a range of small molecules in development that have been shown to reduce angiogenesis in in vitro assays.

For a summary of the licensing opportunities arising out of this project visit LICENSING OPPORTUNITIES.
Dendrimer-cisplatin complex...

Cisplatin is a drug commonly used for the treatment of cancer. However, treatment with cisplatin is associated with significant side effects that limit the success achievable with the drug. Starpharma, in collaboration with Dendritic Nanotechnologies, Inc., is examining the potential of a dendrimer-cisplatin complex to act as a delivery agent. Cisplatin can be complexed with the dendrimer, protecting the cisplatin.

For more information, see flyer Novel Chemotherapeutic Agents.
Biodefense and Tropical Diseases

The US government is providing significant funding to research programs aimed at improving detection and countering of bioterrorist attacks. Starpharma’s development programs in this area focus on dendrimer-based products with activity against:

* exotic viral diseases (e.g. Ebola virus);
* toxins (e.g. Cholera toxin).

Dendrimers possess several advantages as drugs or surface decontamination agents:

* polyvalent (multiple surface groups results in efficient attachment to biological target sites);
* do not induce antigenic activity (no immune response);
* stable (use in a wide variety of environments and formulations);
* low toxicity (safe to use);
* predictable properties (easily tailored to give desired effects).